Serine protease inhibitor Kazal type 1 (SPINK1) drives proliferation and anoikis resistance in a subset of ovarian cancers

Christine Mehner; Ann L. Oberg; Kimberly R. Kalli; Aziza Nassar; Alexandra Hockla; Devon Pendlebury; Magdalena A. Cichon; Krista M. Goergen; Matthew J. Maurer; Ellen L. Goode; Gary L. Keeney; Aminah Jatoi; Miklós Sahin-Tóth; John A. Copland; Derek C. Radisky; Evette S. Radisky

doi:10.18632/oncotarget.5927

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Papers:

Serine protease inhibitor Kazal type 1 (SPINK1) drives proliferation and anoikis resistance in a subset of ovarian cancers

Christine Mehner, Ann L. Oberg, Kimberly R. Kalli, Aziza Nassar, Alexandra Hockla, Devon Pendlebury, Magdalena A. Cichon, Krista M. Goergen, Matthew J. Maurer, Ellen L. Goode, Gary L. Keeney, Aminah Jatoi, Miklós Sahin-Tóth, John A. Copland, Derek C. Radisky and Evette S. Radisky _

PDF | HTML | How to cite

Oncotarget. 2015; 6:35737-35754. https://doi.org/10.18632/oncotarget.5927

Metrics: PDF 1882 views | HTML 2879 views | ?

Abstract

Christine Mehner1, Ann L. Oberg2, Kimberly R. Kalli3, Aziza Nassar4, Alexandra Hockla1, Devon Pendlebury1, Magdalena A. Cichon1, Krista M. Goergen2, Matthew J. Maurer2, Ellen L. Goode5, Gary L. Keeney6, Aminah Jatoi3, Miklós Sahin-Tóth7, John A. Copland1, Derek C. Radisky1 and Evette S. Radisky1

1 Department of Cancer Biology, Mayo Clinic, Jacksonville, FL, USA

2 Division of Biomedical Statistics and Informatics, Department of Health Sciences Research, Mayo Clinic, Rochester, MN , USA

3 Department of Medical Oncology, Mayo Clinic, Rochester, MN, USA

4 Department of Laboratory Medicine and Pathology, Mayo Clinic, Jacksonville, FL, USA

5 Division of Epidemiology, Department of Health Sciences Research, Mayo Clinic, Rochester, MN, USA

6 Division of Anatomic Pathology, Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA

7 Department of Molecular and Cell Biology, Boston University Henry M. Goldman School of Dental Medicine, Boston, MA, USA

Correspondence to:

Evette S. Radisky, email:

Keywords: SPINK1, ovarian cancer, serine protease inhibitor, EGFR, anoikis

Received: July 07, 2015 Accepted: September 14, 2015 Published: September 30, 2015

Abstract

Ovarian cancer represents the most lethal tumor type among malignancies of the female reproductive system. Overall survival rates remain low. In this study, we identify the serine protease inhibitor Kazal type 1 (SPINK1) as a potential therapeutic target for a subset of ovarian cancers. We show that SPINK1 drives ovarian cancer cell proliferation through activation of epidermal growth factor receptor (EGFR) signaling, and that SPINK1 promotes resistance to anoikis through a distinct mechanism involving protease inhibition. In analyses of ovarian tumor specimens from a Mayo Clinic cohort of 490 patients, we further find that SPINK1 immunostaining represents an independent prognostic factor for poor survival, with the strongest association in patients with nonserous histological tumor subtypes (endometrioid, clear cell, and mucinous). This study provides novel insight into the fundamental processes underlying ovarian cancer progression, and also suggests new avenues for development of molecularly targeted therapies.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 5927

Publication Alerts

Research Papers:

Serine protease inhibitor Kazal type 1 (SPINK1) drives proliferation and anoikis resistance in a subset of ovarian cancers

Abstract